Zoledronic acid	Placebo	Subsequent subtrochanteric fractures 	9878	10019	There were two subsequent subtrochanteric fractures reported as adverse events: one in the zoledronic acid group and one in the placebo group
Zoledronic acid	Placebo	Subsequent subtrochanteric fractures 	9878	10020	There were two subsequent subtrochanteric fractures reported as adverse events: one in the zoledronic acid group and one in the placebo group.
Zoledronic acid	Placebo	New hip fractures	9713	9876	In the overall study population, the rate of new hip fractures was 2.0% (23/1,065) in the zoledronic acid group and 3.5% (33/1,062) in the placebo group (P = 0.18)
Zoledronic acid	Placebo	Intertrochanteric location	-1	-1	Intertrochanteric <TAB> 358 (33.6) <TAB> 344 (32.4)
Zoledronic acid	Placebo	Subcapital location	-1	-1	ubcapital <TAB> 220 (20.7) <TAB> 213 (20.1)
Zoledronic acid	Placebo	Subcapital location	-1	-1	<td align="left">Subcapital</td><td align="char" char="(">220 (20.7)</td><td align="char" char="(">213 (20.1)</td>
Zoledronic acid	Placebo	New hip fractures	9713	9877	In the overall study population, the rate of new hip fractures was 2.0% (23/1,065) in the zoledronic acid group and 3.5% (33/1,062) in the placebo group (P = 0.18).
Zoledronic acid	Placebo	Adverse effects on the healing of fractures	10271	10394	Further, in the safety analysis of the overall study population, no adverse effects on the healing of fractures were noted.
